{
    "Trade/Device Name(s)": [
        "N Antisera to Human \u03b12-Macroglobulin Assay",
        "N Antisera to Human \u03b12-Macroglobulin Immunological Test System"
    ],
    "Submitter Information": "Dade Behring Marburg GmbH",
    "510(k) Number": "K053073",
    "Predicate Device Reference 510(k) Number(s)": [
        "K860894"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DEB"
    ],
    "Summary Letter Date": "March 28, 2006",
    "Summary Letter Received Date": "November 1, 2005",
    "Submission Date": "October 28, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.5620"
    ],
    "Regulation Name(s)": [
        "Alpha-2-Macroglobulin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "\u03b12-Macroglobulin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Heparinized plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BN\u2122 Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Immunonephelometry"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Test System"
    ],
    "Document Summary": "FDA 510(k) summary for N Antisera to Human \u03b12-Macroglobulin Assay for quantitative measurement via immunonephelometry on BN Systems",
    "Indications for Use Summary": "For in vitro quantitative determination of \u03b12-macroglobulin in human serum and heparinized plasma; measurement may aid diagnosis of blood clotting or clot lysis disorders",
    "fda_folder": "Immunology"
}